Amgen Inc. (NASDAQ:AMGN) Shares Sold by Symphony Financial Ltd. Co.

Symphony Financial Ltd. Co. decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 39.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,147 shares of the medical research company’s stock after selling 2,082 shares during the period. Symphony Financial Ltd. Co.’s holdings in Amgen were worth $696,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AMGN. Roundview Capital LLC lifted its stake in Amgen by 1.3% during the first quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock worth $2,027,000 after purchasing an additional 107 shares during the last quarter. Merit Financial Group LLC lifted its stake in Amgen by 39.2% in the first quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock valued at $555,000 after buying an additional 647 shares during the last quarter. Ergoteles LLC acquired a new position in shares of Amgen in the first quarter valued at approximately $219,000. First Western Trust Bank acquired a new position in shares of Amgen in the first quarter valued at approximately $334,000. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in Amgen by 2.1% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock worth $5,970,000 after acquiring an additional 513 shares during the period. Hedge funds and other institutional investors own 74.44% of the company’s stock.

Amgen Trading Up 0.3 %

Amgen stock traded up $0.81 during mid-day trading on Tuesday, hitting $263.96. 623,765 shares of the company’s stock were exchanged, compared to its average volume of 2,448,766. The company’s 50 day simple moving average is $248.12 and its 200-day simple moving average is $237.72. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $296.67. The firm has a market capitalization of $141.19 billion, a P/E ratio of 17.74, a PEG ratio of 3.28 and a beta of 0.61. The company has a quick ratio of 2.48, a current ratio of 2.77 and a debt-to-equity ratio of 8.76.

Amgen (NASDAQ:AMGNGet Free Report) last released its earnings results on Thursday, August 3rd. The medical research company reported $5.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.44 by $0.56. Amgen had a return on equity of 196.60% and a net margin of 30.02%. The business had revenue of $7 billion for the quarter, compared to the consensus estimate of $6.66 billion. During the same quarter in the previous year, the business earned $4.65 earnings per share. Amgen’s quarterly revenue was up 6.2% on a year-over-year basis. On average, equities analysts anticipate that Amgen Inc. will post 18.35 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Friday, August 18th were issued a dividend of $2.13 per share. The ex-dividend date of this dividend was Thursday, August 17th. This represents a $8.52 annualized dividend and a dividend yield of 3.23%. Amgen’s dividend payout ratio (DPR) is presently 57.45%.

Insider Buying and Selling

In other Amgen news, EVP Murdo Gordon sold 9,558 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $262.43, for a total transaction of $2,508,305.94. Following the sale, the executive vice president now owns 44,308 shares of the company’s stock, valued at $11,627,748.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.57% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and issued a $280.00 target price on shares of Amgen in a research note on Tuesday, July 25th. Credit Suisse Group cut their target price on Amgen from $220.00 to $200.00 in a research note on Wednesday, July 12th. StockNews.com upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 8th. Royal Bank of Canada lifted their price target on Amgen from $250.00 to $253.00 and gave the company a “sector perform” rating in a research report on Friday, August 4th. Finally, HSBC began coverage on Amgen in a report on Wednesday, September 6th. They set a “buy” rating and a $320.00 price target on the stock. Two analysts have rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $265.44.

Read Our Latest Stock Analysis on Amgen

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.